BRIEF-AstraZeneca's Medimmune partners Mirati for immuno-oncology combination in lung cancer
August 05, 2015 at 02:10 AM EDT
* Medimmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer 5 August 2015
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.